Search
Melanoma (Skin) Clinical Trials
A listing of 8 Melanoma (Skin) clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 8 of 8
There are currently 8 active clinical trials seeking participants for Melanoma (Skin) research studies. The states with the highest number of trials for Melanoma (Skin) participants are Ohio, Illinois, Minnesota and Michigan.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ENV-501 in Patients With HER3-Expressing Solid Tumors
Recruiting
This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of ENV-501 in patients with advanced-stage, relapsed and/or refractory human epidermal growth factor receptor 3 (HER3)-expressing solid tumors. The study consists of 2 phases: a dose escalation phase (Phase 1) and a dose expansion phase (Phase 2).
The primary objectives of Phase 1 are to characterize the overall safety and tolerability profile of in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Research Site, La Jolla, California +3 locations
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
Recruiting
To learn if giving nivolumab in combination with relatlimab can help to control melanoma that has spread to the brain (melanoma with brain metastases). The safety and side effects of the study drug combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Melanoma (Skin)
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
Recruiting
The purpose of this study is to determine whether high-intensity exercise and high-fiber diet are feasible and improve various health outcomes among participants with advanced melanoma receiving immunotherapy.
The names of the groups in this research study are:
* High-Intensity Exercise (EX)
* High-fiber Diet (DT)
* Combined High-Intensity Exercise and High-Fiber Diet (COMB)
* Attention Control (AC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Melanoma (Skin), Skin Cancer, Advanced Melanoma
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
Recruiting
In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with Nivolumab in subjects with unresectable and metastatic melanoma.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/23/2025
Locations: Biogenix Molecular, Miami, Florida +9 locations
Conditions: Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Mucosal Melanoma, Melanoma Stage III
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
Recruiting
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: University of Birmingham Alabama, Birmingham, Alabama +52 locations
Conditions: Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
Recruiting
This is a phase 2, single-arm, open label clinical trial determining efficacy of Cyclophosphamide and Pembrolizumab in subjects with melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: Chao Family Comprehensive Cancer Center University of California, Irvine, Orange, California
Conditions: Melanoma, Melanoma Stage III, Melanoma (Skin), Melanoma Stage IV
Rural Adult and Youth Sun Protection Study
Recruiting
The purpose of this study is to help prevent skin cancer by improving the use of sun protective behaviors among youths living in rural communities in Utah and West Virginia.
Gender:
ALL
Ages:
Between 3 years and 7 years
Trial Updated:
12/12/2024
Locations: University of Utah, Salt Lake City, Utah +1 locations
Conditions: Melanoma (Skin), Skin Cancer
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
Recruiting
The goal of this study is to observe metabolic features associated with human melanoma tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Melanoma (Skin)
1 - 8 of 8